Twelve-month follow-up data for the first two patients treated have been reported and demonstrate the safety of the product and promising efficacy results for these first two patients treated.
Promising results also will be presented from the first patients treated with ATA-200 gene therapy in a clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy.
Il est rapporté les données de suivi à 9 mois (incluant les biopsies musculaires faites à 6 mois) chez les 2 premiers patients traités : la sécurité du produit est démontrée et les résultats d’efficacité chez ces deux premiers patients traités sont très encourageants.
Atamyo Therapeutics a clinical-stage biotechnology company focused on the development of new generation gene therapies targeting muscular dystrophies and cardiomyopathies, today announced that the U.S. Food & Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ATA-200 to proceed in a Phase 1b/2b clinical trial.
Atamyo also announced the filing of an Investigational New Drug (IND) application with the US FDA for a Phase 1b/2b clinical trial of its gene therapy, ATA-200, for patients with LGMD-2C/R5.
Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, today announced the filing of a Clinical Trial Application (CTA) in Europe for ATA-200, its gene therapy targeting γ-sarcoglycan (SGCG) related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5).